About the Position
We are seeking a talented and highly motivated scientist to join our Library Discovery team and help us augment our DNA encoded library collection. The key objective for this position is to identify and solve key bottlenecks in the DEL pipeline and develop innovative next generation improvements to the underlying technology. Broad scientific interests spanning biology, chemistry, and drug discovery highly desirable. Responsibilities may also include library development and selection analysis.
- BS, MS, or PhD in life sciences (ex. chemistry, biochemistry, biology) with 0-5 years industrial chemistry experience (years of relevant experience will impact level of hire).
- Training in molecular biology methods and high throughput assay development
- Interest and ability to apply solutions from disparate fields of science and engineering to solve problems in the DEL technology platform and drug discovery in general
- Must have ability to work independently; Be highly self-directed and self-motivated
- High level of creativity and productivity with strong problem-solving skills.
- High level of attention to detail and good organizational skills.
- Excellent communication skills and able to present the rationale, key data, issues and accomplishments to other members of the department.
Fit with Nurix Culture and Values
- Strongly team-oriented; highly collaborative
- Hands-on approach; resourceful and open to diverse points of view
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.